WaveMan
WaveMan · Company
BNR · Burning Rock Biotech Ltd
> Search tickers & screens ⌘K
LIVE
← All companies

BNR Burning Rock Biotech (BNR) Insider Trading, Ownership & Congress Trades

Healthcare Services · Services-medical laboratories · CIK 0001792267
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
10
13F, latest reported quarter

What the filings say about BNR

Insiders, 180 days
+$6.2M net bought
1 buyer

Burning Rock Biotech insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Burning Rock Biotech Ltd insiders bought a net $6.2M of stock across 8 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.

Insider
Filed
Shares
Value
Since filing
Han Yusheng
Director
BUY
2026-07-02 SECtraded 2026-06-26
24,900
$199.1K
+14.9%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Jun 24, 2026.
  • +42.7% median (+48.9% mean) 90-day return after 7 previous buys.
  • The trade is 0.1% of the 18,404,086 shares held after it.
  • No other insider bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Han Yusheng bought about $199.1K of BNR on Jun 26, 2026; 10 funds added in the latest 13F quarter.
Han Yusheng
Director
BUY
2026-07-02 SECtraded 2026-06-24
250,000
$2.0M
+14.9%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Jun 23, 2026.
  • +39.2% median (+41.5% mean) 90-day return after 6 previous buys.
  • The trade is 1.4% of the 18,379,186 shares held after it.
  • No other insider bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Han Yusheng bought about $2.0M of BNR on Jun 24, 2026; 10 funds added in the latest 13F quarter.
Han Yusheng
Director
BUY
2026-07-02 SECtraded 2026-06-23
5,990
$44.9K
+14.9%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Jun 22, 2026.
  • +35.8% median (+30.9% mean) 90-day return after 5 previous buys.
  • The trade is 0.0% of the 18,129,186 shares held after it.
  • No other insider bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Han Yusheng bought about $44.9K of BNR on Jun 23, 2026; 10 funds added in the latest 13F quarter.
Han Yusheng
Director
BUY
2026-07-02 SECtraded 2026-06-22
104,650
$779.7K
+14.9%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Jun 16, 2026.
  • +35.5% median (+16.0% mean) 90-day return after 4 previous buys.
  • The trade is 0.6% of the 18,123,196 shares held after it.
  • No other insider bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Han Yusheng bought about $779.7K of BNR on Jun 22, 2026; 10 funds added in the latest 13F quarter.
Han Yusheng
Director
BUY
2026-07-02 SECtraded 2026-06-16
111,110
$1.0M
+14.9%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jun 12, 2026.
  • +35.3% median (+7.1% mean) 90-day return after 3 previous buys.
  • The trade is 0.6% of the 18,018,546 shares held after it.
  • No other insider bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Han Yusheng bought about $1,000.0K of BNR on Jun 16, 2026; 10 funds added in the latest 13F quarter.
8 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 3 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$6.2M over 180 days
more than 98% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
10 funds bought in last quarter
below 94% of Healthcare Services
Revenue
+9.2% year over year
below 56% of Healthcare Services
Margin
-10.3% net margin
below 73% of Healthcare Services
Buybacks
no share repurchases reported
Short interest
1.2% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 7 in the prior 90
Why it matters
The absence is the signal: 7 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch BNR

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+13.0%12M
-33%+75%+183%+291%2025-102025-122026-022026-042026-062026-082026-10 2026-03-31 · Han Yusheng bought $5.5M2026-06-24 · Han Yusheng bought $2.0M2026-06-12 · Han Yusheng bought $1.9M2026-06-16 · Han Yusheng bought $1,000.0K2026-06-22 · Han Yusheng bought $779.7K2026-06-11 · Han Yusheng bought $216.4K2026-06-26 · Han Yusheng bought $199.1K2026-06-23 · Han Yusheng bought $44.9K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BNR: institutional holders (13F)

13F holdings, latest reported quarter
Kynam Capital Management, LP
1,238,563 sh
$10.5M
CRCM LP
423,994 sh
$3.5M
RENAISSANCE TECHNOLOGIES LLC
52,838 sh
$442.3K
MORGAN STANLEY
43,594 sh
$364.9K
Amova Asset Management Americas, Inc.
29,724 sh
$257.7K

Congress trades in BNR

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BNR planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

BNR mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Golden Dragon China ETF
$34.0K position · as of 2026-07-31
0.0%
Emerging Markets Social Core Equity Portfolio
$10.8K position · as of 2026-07-31
0.0%
THE EMERGING MARKETS SMALL CAP SERIES
$8.1K position · as of 2026-07-31
0.0%
Fidelity Nasdaq Composite Index Fund
$36.9K position · as of 2026-05-31
0.0%
World ex U.S. Core Equity Portfolio
$5.4K position · as of 2026-07-31
0.0%
EMERGING MARKETS CORE EQUITY 2 PORTFOLIO
$12.0K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $6.2M bought by insiders over 180 days, 10 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
NTRACSTLPGNYHIMSWGSPRVATDOCAVAHGHADUSSERABDSX

BNR financials

Revenue growth
+9.2%
XBRL, annual
Net margin
-10.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Debt to equity
0.00x
long-term 2025-12-31 plus current 2022-12-31; equity 2025-12-31
Cash flow to debt
n/a
needs four quarters of operating cash flow
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
n/a
no share count filed
FCF yield
n/a
no share count filed
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$539.6M$515.8M$537.4M$563.2M
Gross profit$402.9M$362.4M$363.2M$380.0M
Operating income-$54.8M-$357.6M-$669.3M-$980.4M
Net income-$55.3M-$346.6M-$653.7M-$971.2M
Operating cash flow-$28.4M-$92.3M-$255.8M-$456.8M
Cash$478.4M$519.8M$615.1M$905.5M
Long-term debt$1.7M$0n/an/a
SEC XBRL, fiscal years, as known on 2026-10-28

BNR Stock Sonar score 5/7 axes

Find similar shapesCompare

BNR ranks highest on financial health (83rd percentile) and insider conviction (81st), and lowest on institutional and government (6th), among Healthcare Services peers.

HealthGrowthInsidersInstitutionsRisk
Financial health
83
Inputs
  • Debt to equity0.00x · 83 pct, sector of 61
  • Cash flow to debtneeds four quarters of operating cash flow
Growth
44
Inputs
  • Revenue growth, YoY+9.2% · 44 pct, sector of 87
  • Backlog growth, YoY+0.3% · 44 pct, universe of 854
Insider conviction
81
Inputs
  • Net Form 4 buying (codes P and S), 180d$6.2M · 98 pct, sector of 64
  • Insider buyers, 180d1 · 63 pct, sector of 64
Institutional and government
6
Inputs
  • Funds adding, latest quarter10 · 6 pct, sector of 73
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
74
Inputs
  • Short interest, % of float+1.2% · 74 pct, sector of 95
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Profitability, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

BNR filings, in plain words

Are Burning Rock Biotech insiders buying or selling BNR?

In the 180 days to 2026-10-28, Burning Rock Biotech insiders were net buyers, a net $6.2M across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, Burning Rock Biotech insiders were net buyers of BNR, a net $6.2M across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies